Positioning of Melflufen in Heavily Pretreated RRMM Patients: Real-World Evidence in a Rapidly Evolving Therapeutic Landscape - PubMed
a day ago
- #multiple myeloma
- #melflufen
- #real-world evidence
- Melflufen plus dexamethasone is approved for triple-class-refractory multiple myeloma (MM) patients after ≥3 prior therapies.
- Real-world data from 17 relapsed/refractory MM patients showed an overall response rate of 41%.
- Median progression-free survival (mPFS) was 3.7 months overall and 9.0 months in responders.
- Median overall survival (mOS) was not reached in the total population or subgroups.
- Grade ≥3 hematologic toxicities were common (anemia 35%, neutropenia 53%, thrombocytopenia 53%).
- Grade ≥3 nonhematologic events were less frequent (fatigue 6%, infections 23.5%).
- No secondary primary malignancies were recorded.
- Melflufen-dexamethasone is effective and has a manageable safety profile, even in elderly patients.
- It may be an option for patients refractory to novel immunotherapies or not ideal candidates for such treatments.